Anthropic has launched two new fifth-generation AI models: Claude Fable 5 for general use and Claude Mythos 5, which is initially available only to selected partners for specialized areas such as cyber security. Fable 5 outperforms all of Anthropic's previous models, achieving top scores in benchmarks for programming, image processing, and complex data analysis, while Mythos 5 shows strong performance in drug design and operates largely autonomously in genomics research. The new models come at a price of 10 US dollars per million input tokens, making them nearly twice as expensive as the Claude Opus 4.8 model, with token efficiency still to be determined.
Fable 5 claims the top spot in nearly all benchmarks, while Claude Mythos 5 (no longer in preview) is still only available to select partners. Both models share the same base model. Fable 5 ships with conservative safety guardrails for general use. Mythos 5 drops those restrictions in areas like cybersecurity and is reserved for a small group of partners. Anthropic says Fable 5 beats every generally available model the company has ever shipped and claims state-of-the-art results in nearly all benchmarks tested. The gap widens on long, complex tasks, the company states.
Anthropic's internal protein design experts say Mythos 5 sped up parts of the drug design process by 10x. In one test, the model, equipped with protein design and bioinformatics tools but no human help, matched or beat experienced human operators. It handled every step a scientist would: it picked binding sites, launched and ran protein design tools, and fixed errors on its own. Nine out of 14 protein targets yielded strong drug design candidates, which are now being studied. Anthropic's biggest claim is that Mythos 5 is the first model to consistently produce novel and convincing scientific hypotheses, something that's highly debated when it comes to current LLMs.
Source: thedecoder
